RxDoctor Payments Data

Gary Kauffman, MD

Interventional Cardiology · Phoenix, AZNPI 1386645489

Payments from drug & device makers

$1,027in general payments, 2019–2025

Across 68 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$277
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$126
  • Amgen$111
  • AstraZeneca$81
  • E.r. Squibb & Sons, L.L.C.$69
  • Boehringer Ingelheim$54
  • plus $309 from 13 others

What the payments were for

  • Food & beverage$1,022100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,027 in reported general payments places this provider in the 10th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$244,704
Medicare patients
775
Services billed
3,408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban487$515,737
XareltoRivaroxaban132$153,604
EntrestoSacubitril/Valsartan90$91,054
FarxigaDapagliflozin Propanediol53$41,721
JardianceEmpagliflozin21$21,982
Repatha SureclickEvolocumab23$19,836
Praluent PenAlirocumab26$17,557
BrilintaTicagrelor18$14,958
Metoprolol Succinate594$6,638
Olmesartan Medoxomil305$5,683
Nebivolol Hcl115$5,472
Atorvastatin Calcium546$5,307
Rosuvastatin Calcium405$5,206
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide130$4,406
ClopidogrelClopidogrel Bisulfate337$4,162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25$515,737487 claims
Johnson & JohnsonXarelto$277$153,604132 claims
NovartisEntresto$20$91,05490 claims
AstraZenecaFarxiga, Brilinta$81$56,67971 claims
Boehringer IngelheimJardiance$54$21,98221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →